Upstream Bio, Inc. UPB
Set alert
3.41 USD +0.14 +4.28%
At close · Oct 30
3.35 -0.06 -1.76%
After hours · Oct 30, 4:44 PM ET
3.15 Day range 3.43
2.74 52-week range 32.60
- YTD
- -87.44%
- 1 year
- -86.77%
- Open
- 3.26
- Prev close
- 3.27
- Mkt cap
- 186.77M
- Vol
- 946.13K
- Avg vol
- 846.31K
- EPS
- -2.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.15
- High
- 3.43
- Forward P/E
- -2.45
- Beta
- 0.00
- Short ratio
- 2.45
- Inst. own
- 94.73%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 18.55
- 200-d avg
- 19.11
- 1y target
- 47.86
MAX chart
Events in this range
- Nov 5, 2024Rating: JP Morgan · — → Overweight
- Oct 14, 2025Rating: Truist Securities · — → Buy
- Nov 18, 2025Rating: Evercore ISI Group · — → Outperform
- Dec 2, 2025Rating: LifeSci Capital · — → Outperform
- Dec 18, 2025Rating: Mizuho · — → Outperform
- Mar 27, 2026Downgrade: Evercore ISI Group · Outperform → In-Line
Signals (20)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 29, 2026 | 2 days ago |
| MACD: Sell Signal | Oct 19, 2026 | 1 week ago |
| RSI: Oversold | Oct 5, 2026 | 3 weeks ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 3, 2026 | 2 months ago |
| MACD: Buy Signal | Jun 29, 2026 | 4 months ago |
| RSI: Oversold | Jun 8, 2026 | 4 months ago |
| SMA: Bearish | May 4, 2026 | 6 months ago |
| RSI: Oversold | Feb 23, 2026 | 8 months ago |
| SMA: Bearish | Feb 9, 2026 | 8 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| RSI: Overbought | Dec 15, 2025 | 10 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| RSI: Overbought | Oct 27, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| SMA: Bullish | Apr 14, 2025 | 1 year ago |
| SMA: Bearish | Mar 17, 2025 | 1 year ago |
| SMA: Bullish | Mar 10, 2025 | 1 year ago |
Key statistics
- Market cap
- 468.51M
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- -2.45
- PEG ratio
- 0.00
- Price / sales
- 164.16
- Price / book
- 1.38
- EPS (TTM)
- -2.65
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 2.85M
- Revenue growth
- 9.00%
- Free cash flow
- 0
- Total cash
- 341.51M
- Total debt
- 1.27M
- Return on equity
- -35.44%
- Shares outstanding
- 54.04M
- Short % of float
- 15.85%
- 50-day average
- 18.55
- 200-day average
- 19.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.86 +1303.4% upside
Now 3.41
- Target (low)
- 35.00
- Target (mean)
- 47.86
- Target (high)
- 75.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.76667.
Financials — quick view
UPB Revenue — quarterly 773.00K
UPB Net income — quarterly -39.70M
UPB EPS — quarterly -0.73
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 27, 2026 | Evercore ISI Group | down | Outperform | In-Line |
| Dec 18, 2025 | Mizuho | init | — | Outperform |
| Dec 2, 2025 | LifeSci Capital | init | — | Outperform |
| Nov 18, 2025 | Evercore ISI Group | init | — | Outperform |
| Oct 14, 2025 | Truist Securities | init | — | Buy |
| Nov 5, 2024 | JP Morgan | init | — | Overweight |
About Upstream Bio, Inc.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- upstreambio.com
News
- Analyzing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)
- These beaten-down stocks could bounce back in January, if history is any guide
- Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
- HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
- Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
- Fannie Mae Announces Sale of Non-Performing Loans
- JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9
- Truist Securities Maintains Buy on Upstream Bio, Lowers Price Target to $25
- Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
- Upstream Bio Q2 EPS $(0.73) Beats $(0.76) Estimate, Sales $773.000K Beat $430.714K Estimate
Your note
Sign in to keep a note on UPB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AI UPSTREAM LLC | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| AMBROSE ALLISON | General Counsel | Sale | Mar 15, 2026 | 16,525 |
| CHIMOVITS EREZ | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 14, 2024 | 0 |
| DEYKIN AARON M.D. | Officer | Sale | Mar 15, 2026 | 32,687 |
| GRAY MICHAEL P | Chief Operating Officer | Sale | Mar 15, 2026 | 29,648 |
| HOUGHTON ADAM | Officer | Sale | Mar 15, 2026 | 24,301 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 13.91% | 7,518,202 | 65.18M | Dec 30, 2025 |
| Orbimed Advisors LLC. | 10.54% | 5,693,589 | 49.36M | Dec 30, 2025 |
| Blackrock Inc. | 6.19% | 3,344,504 | 29.00M | Dec 30, 2025 |
| Decheng Capital LLC | 5.82% | 3,143,078 | 27.25M | Dec 30, 2025 |
| NORGES BANK | 5.33% | 2,882,647 | 24.99M | Dec 30, 2025 |
| Enavate Sciences Gp, LLC | 4.55% | 2,459,703 | 21.33M | Dec 30, 2025 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.67% | 1,443,025 | 12.51M | Dec 30, 2025 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 2.54% | 1,371,372 | 11.89M | Dec 30, 2025 |
| Fidelity Select Portfolios-Select Health Care Portfolio | 1.48% | 800,000 | 6.94M | Jan 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.44% | 780,261 | 6.76M | Jan 30, 2026 |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 1.28% | 691,003 | 5.99M | Jan 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth K6 Fund | 1.26% | 682,018 | 5.91M | Dec 30, 2025 |